RxDoctor Payments Data

Brenda Meza

Family · Brownsville, TXNPI 1336501253

Payments from drug & device makers

$1,838in general payments, 2019–2025

Across 39 payments — averaging $47.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$382
  • Amgen$188
  • Eisai Inc.$157
  • Novartis$151
  • Jazz Pharmaceuticals Inc.$150
  • AstraZeneca$139
  • plus $670 from 15 others

What the payments were for

  • Food & beverage$1,838100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,838 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$34,563
Medicare patients
103
Services billed
2,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor24$13,886
Aimovig AutoinjectorErenumab-Aooe12$12,203
Topiramate ErTopiramate13$12,004
Rivastigmine53$11,130
NamzaricMemantine Hcl/Donepezil Hcl17$10,188
NeuproRotigotine11$8,589
Ajovy SyringeFremanezumab-Vfrm11$8,318
Levetiracetam192$6,402
Memantine Hcl224$4,452
Carbamazepine ErCarbamazepine32$2,698
RivastigmineRivastigmine Tartrate67$2,403
Donepezil Hcl328$2,125
Gabapentin198$2,080
Carbamazepine26$1,256
Carbidopa-LevodopaCarbidopa/Levodopa87$1,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$139$13,88624 claims
AbbVieNamzaric$71$10,18817 claims
UCB, Inc.Neupro$24$8,58911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Brownsville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →